Xencor (XNCR) Payables (2013 - 2026)
Xencor (XNCR) posted quarterly Payables of $7.9 million for Q1 2026, down 51.09% year-over-year from $16.2 million in Q1 2025, and down 26.87% quarter-over-quarter from $10.8 million in Q4 2025.
Xencor (XNCR) Payables (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Payables for 14 consecutive years, with $7.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 51.09% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $7.9 million (down 51.09% YoY), while the FY2025 annual figure was $10.8 million, down 35.39% from the prior year.
- Payables fell to $7.9 million in Q1 2026 per XNCR's latest filing, from $10.8 million in the prior quarter.
- Across five years, Payables topped out at $18.8 million in Q3 2024 and bottomed at $7.9 million in Q1 2026.
- Historically, Payables has averaged $14.2 million across 5 years, with a median of $15.0 million in 2023.
- Annual changes were most pronounced in 2022 — Payables soared 121.41% — and 2025, when it sank 51.63%.
- Xencor's Payables stood at $10.1 million in 2022, then surged by 37.93% to $13.9 million in 2023, then advanced by 20.45% to $16.8 million in 2024, then sank by 35.39% to $10.8 million in 2025, then declined by 26.87% to $7.9 million in 2026.
- Business Quant data shows XNCR's Payables at $7.9 million in Q1 2026, $10.8 million in Q4 2025, and $9.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 12.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.65 Mn |
| Mar 31, 2026 | 7.92 Mn |
| Dec 31, 2025 | 10.83 Mn |
| Sep 30, 2025 | 9.08 Mn |
| Jun 30, 2025 | 18.53 Mn |
| Mar 31, 2025 | 16.19 Mn |
| Dec 31, 2024 | 16.76 Mn |
| Sep 30, 2024 | 18.77 Mn |
| Jun 30, 2024 | 15.84 Mn |
| Mar 31, 2024 | 16.01 Mn |
| Dec 31, 2023 | 13.91 Mn |
| Sep 30, 2023 | 14.97 Mn |
| Jun 30, 2023 | 14.10 Mn |
| Mar 31, 2023 | 15.34 Mn |
| Dec 31, 2022 | 10.09 Mn |
| Sep 30, 2022 | 14.62 Mn |
| Jun 30, 2022 | 15.75 Mn |
| Mar 31, 2022 | 11.91 Mn |
| Dec 31, 2021 | 14.00 Mn |
| Sep 30, 2021 | 9.13 Mn |